Literature DB >> 23025805

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.

Tao Liu1, Somarajan J Nair, André Lescarbeau, Jitendra Belani, Stéphane Peluso, James Conley, Bonnie Tillotson, Patrick O'Hearn, Sherri Smith, Kelly Slocum, Kip West, Joseph Helble, Mark Douglas, Adilah Bahadoor, Janid Ali, Karen McGovern, Christian Fritz, Vito J Palombella, Andrew Wylie, Alfredo C Castro, Martin R Tremblay.   

Abstract

Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23025805     DOI: 10.1021/jm3011542

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

1.  The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.

Authors:  Dakota N Jackson; Kibrom M Alula; Yaritza Delgado-Deida; Redouane Tabti; Kevin Turner; Xuan Wang; K Venuprasad; Rhonda F Souza; Laurent Désaubry; Arianne L Theiss
Journal:  Cancer Res       Date:  2020-07-14       Impact factor: 12.701

2.  A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues.

Authors:  Han Yueh; Qiwen Gao; John A Porco; Aaron B Beeler
Journal:  Bioorg Med Chem       Date:  2017-06-11       Impact factor: 3.641

Review 3.  Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

Authors:  Li Pan; John L Woodard; David M Lucas; James R Fuchs; A Douglas Kinghorn
Journal:  Nat Prod Rep       Date:  2014-05-02       Impact factor: 13.423

4.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

Review 5.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

6.  Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation.

Authors:  Anna Sobol; Caroline Askonas; Sara Alani; Megan J Weber; Vijayalakshmi Ananthanarayanan; Clodia Osipo; Maurizio Bocchetta
Journal:  Mol Cancer Res       Date:  2016-11-18       Impact factor: 5.852

Review 7.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

8.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Authors:  Heather Sadlish; Gabriela Galicia-Vazquez; C Gregory Paris; Thomas Aust; Bhupinder Bhullar; Lena Chang; Stephen B Helliwell; Dominic Hoepfner; Britta Knapp; Ralph Riedl; Silvio Roggo; Sven Schuierer; Christian Studer; John A Porco; Jerry Pelletier; N Rao Movva
Journal:  ACS Chem Biol       Date:  2013-05-07       Impact factor: 5.100

9.  Synthesis of Aza-Rocaglates via ESIPT-Mediated (3+2) Photocycloaddition.

Authors:  Wenyu Wang; Regina Cencic; Luke Whitesell; Jerry Pelletier; John A Porco
Journal:  Chemistry       Date:  2016-07-15       Impact factor: 5.236

10.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Authors:  Francis Robert; William Roman; Alexandre Bramoullé; Christof Fellmann; Anne Roulston; Chaim Shustik; John A Porco; Gordon C Shore; Michael Sebag; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.